Fibrosis Stage-specific Incidence of Hepatocellular Cancer After Hepatitis C Cure With Direct-acting Antivirals: A Systematic Review and Meta-analysis

Kim, Nicole J.; Vutien, Philip; Cleveland, Erin R.; Cravero, Anne; Ioannou, George N.

doi:10.1016/j.cgh.2022.04.013

Cited by 23 publications

(21 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The evolving landscape of HCC etiology, particularly the global rise of NAFLD/MAFLD, continues to hamper the development of effective HCC screening strategy. HCC risk following HCV cure remains high for nearly a decade when cirrhosis is present, and therefore requires HCC screening 74. Alcohol‐associated liver disease remains a major HCC etiology with notable interindividual heterogeneity 234.…”

Section: Future Directions and Conclusionmentioning

confidence: 99%

“…New-generation anti-HBV drugs under development may have a significant effect in predicting HBV-related HCC risk, while viral control/cure may not eliminate the risk as observed in patients with HCV-cured cirrhosis who are at risk for nearly a decade. [74] Serum AFP is currently used as an HCC detection tumor marker, while it is frequently selected as a variable in HCC risk scores. It is empirically known that mild AFP elevation is often observed when hepatic injury and regeneration occur following a transient flare of hepatic inflammation due to active HCV infection, even in the absence of HCC.…”

Section: Hcc Risk Scores Based On Clinical Variablesmentioning

confidence: 99%

See 1 more Smart Citation

Risk stratification and early detection biomarkers for precision HCC screening

et al. 2022

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) mortality remains high primarily due to late diagnosis as a consequence of failed early detection. Professional societies recommend semi-annual HCC screening in at-risk patients with chronic liver disease to increase the likelihood of curative treatment receipt and improve survival. However, recent dynamic shift of HCC etiologies from viral to metabolic liver diseases has significantly increased the potential target population for the screening, whereas annual incidence rate has become substantially lower. Thus, with the contemporary HCC etiologies, the traditional screening approach might not be practical and cost-effective. HCC screening consists of (i) definition of rational at-risk population, and subsequent (ii) repeated application of early detection tests to the population at regular intervals. The suboptimal performance of the currently available HCC screening tests highlights an urgent need for new modalities and strategies to improve early HCC detection. In this review, we overview recent developments of clinical, molecular, and imaging-based tools to address the current challenge, and discuss conceptual framework and approaches of their clinical translation and implementation. These encouraging progresses are expected to transform the current "one-size-fits-all" HCC screening into

show abstract

Section: Future Directions and Conclusionmentioning

confidence: 99%

Section: Hcc Risk Scores Based On Clinical Variablesmentioning

confidence: 99%

Risk stratification and early detection biomarkers for precision HCC screening

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The presence of cirrhosis may affect the treatment duration, the need for ribavirin (RBV) coadministration, and the sustained virologic response (SVR) rates in certain groups of patients [ 19 , 20 , 21 ]. Furthermore, information about the severity of hepatic fibrosis can efficiently help clinicians determine the surveillance strategies for portal hypertension and HCC before and after viral cure [ 22 , 23 , 24 , 25 ]. Currently, percutaneous liver biopsy is the gold standard to stage hepatic fibrosis.…”

Section: Introductionmentioning

confidence: 99%

Noninvasive Diagnosis of Hepatic Fibrosis in Hemodialysis Patients with Hepatitis C Virus Infection

Liu

Kao

2022

Diagnostics

View full text Add to dashboard Cite

Hepatitis C virus (HCV) is a major health problem in hemodialysis patients, which leads to significant morbidity and mortality through progressive hepatic fibrosis or cirrhosis. Percutaneous liver biopsy is the gold standard to stage hepatic fibrosis. However, it is an invasive procedure with postbiopsy complications. Because uremia may significantly increase the risk of fatal and nonfatal bleeding events, the use of noninvasive means to assess the severity of hepatic fibrosis is particularly appealing to hemodialysis patients. To date, researchers have evaluated the performance of various biochemical, serological, and radiological indices for hepatic fibrosis in hemodialysis patients with HCV infection. In this review, we will summarize the progress of noninvasive indices for assessing hepatic fibrosis and propose a pragmatic recommendation to diagnose the stage of hepatic fibrosis with a noninvasive index, in hemodialysis patients with HCV infection.

show abstract

“…8,9 These antiviral therapies have substantially reduced HCC incidences from the viral etiologies, but the patients remain at risk of developing HCC for years. [10][11][12][13] Given the clinically unequivocal predisposing factors, practice guidelines recommend regular HCC screening for HCC detection at early stage amenable to potentially curative surgical or ablative therapies. 14 However, even after the treatment with curative intent, 70% of the patients develop recurrence within 5 years.…”

mentioning

confidence: 99%

“…8 9 These antiviral therapies have substantially reduced HCC incidences from the viral etiologies, but the patients remain at risk of developing HCC for years. 10 11 12 13…”

mentioning

confidence: 99%

Hepatocellular Carcinoma Chemoprevention with Generic Agents

et al. 2022

View full text Add to dashboard Cite

Liver cancer, mainly hepatocellular carcinoma (HCC), remains a major cause of cancer-related death worldwide. With the global epidemic of obesity, the major HCC etiologies have been dynamically shifting from viral to metabolic liver diseases. This change has made HCC prevention difficult with increasingly elusive at-risk populations as rational target for preventive interventions. Besides ongoing efforts to reduce obesity and metabolic disorders, chemoprevention in patients who already have metabolic liver diseases will have a significant impact on the poor HCC prognosis. Hepatitis B- and C-related HCC incidences have been substantially reduced by the new anti-virals, but HCC risk can persist over a decade even after successful viral treatment, highlighting the need for HCC-preventive measures also in these patients. Experimental and retrospective studies have suggested potential utility of generic agents such as lipophilic statins and aspirin for HCC chemoprevention given their well characterized safety profile, although anticipated efficacy may be modest. In this review, we overview recent clinical and translational studies of generic agents in the context of HCC chemoprevention under the contemporary HCC etiologies. We also discuss newly emerging approaches to overcome the challenges in clinical testing of the agents to facilitate their clinical translation.

show abstract

Fibrosis Stage-specific Incidence of Hepatocellular Cancer After Hepatitis C Cure With Direct-acting Antivirals: A Systematic Review and Meta-analysis

Cited by 23 publications

References 51 publications

Risk stratification and early detection biomarkers for precision HCC screening

Risk stratification and early detection biomarkers for precision HCC screening

Noninvasive Diagnosis of Hepatic Fibrosis in Hemodialysis Patients with Hepatitis C Virus Infection

Hepatocellular Carcinoma Chemoprevention with Generic Agents

Contact Info

Product

Resources

About